DNMT3A and acute myeloid leukemia: Pharmacological inhibition of DOT1L by EPZ5676 or EPZ004777 leads to a significant anti-leukemic effect in vitro and in vivo in DNMT3A-mutant AML primary samples and cell lines [27].